Treatment response and survival
PD, death, SD, tumour
TUMOURS, DISEASE, TUMOUR
At the cut‐off date for analysis (6 September 2021), the median follow‐up time was 26.5 months (range 17.6–35.5). Two patients were still receiving treatment. A median of nine doses (range: 1–35) of atezolizumab was administered and five patients completed 2 years of treatment. Median PFS was 4.3 months (95% CI 2.2–8.7). Median OS time was still not reached at the data cut‐off. As the best overall response, four patients had a PR, eight had stable disease (SD) and five had progressive disease (PD). Among the four patients achieving av PR, the median duration of response was 17.8 months. Four patients were not evaluable (NE) according to Clinical outcomes including best overall response (colour of the bar), months to progression (length of the bar), months on treatment (square) and months to death or censure (point) for each individual patient. NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease.The efficacy endpoints focused on the systemic responses, and irradiated lesions were excluded as target lesions. However, when reviewing the treatment effect on irradiated lesions, there were no patients whose non‐irradiated lesions responded better than the irradiated ones. All four patients with PR as the best overall response also had a significant reduction of the irradiated tumours, in two cases leading to a complete radiologic disappearance of the tumour.